Pacylex Pharmaceuticals to Present at Biotech Showcase™ 2023
Edmonton, Alberta, Canada/January 5, 2023 – Pacylex, today announced that CEO Michael Weickert will present an update on clinical progress of PCLX-001 and Series B plans for Pacylex Pharmaceuticals at Biotech Showcase™ 2023.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Pacylex's lead drug candidate, PCLX-001, is currently being evaluated in a Phase 1 clinical study in patients with refractory lymphoma or solid tumors.
- A second Phase 1 study in patients with relapsed or refractory acute myeloid leukemia will begin in Q2 2023.
- Pacylex is raising a Series B to fund two efficacy studies in DMBCL and AML starting in 2023.
Click image above to view full announcement.
About PCLX-001
PCLX-001 is a N-myristoyl-transferase (NMT) inhibitor being developed as a once-a-day pill for leukemia and lymphoma. PCLX-001 selectively and potently inhibits both NMT1 and NMT2 and has been shown to regress lymphoma and leukemia tumors and inhibit the growth of lung and breast cancer tumors in animal models. In leukemia and lymphoma, the levels of NMT2 are correlated with survival, suggesting an important biological role in these cancers. A Phase 1 Trial of PCLX-001 in patients with relapsed/refractory B-cell Non-Hodgkin’s Lymphoma and advanced solid malignancies is currently in progress, and a second Phase 1 trial in patients with relapsed or refractory acute myeloid leukemia (AML) is planned to start Q2 2023. The FDA has granted PCLX-001 Orphan Drug Designation and Fast Track Designation for the treatment of adult patients with relapsed or refractory acute myeloid leukemia.
PCLX-001 is a N-myristoyl-transferase (NMT) inhibitor being developed as a once-a-day pill for leukemia and lymphoma. PCLX-001 selectively and potently inhibits both NMT1 and NMT2 and has been shown to regress lymphoma and leukemia tumors and inhibit the growth of lung and breast cancer tumors in animal models. In leukemia and lymphoma, the levels of NMT2 are correlated with survival, suggesting an important biological role in these cancers. A Phase 1 Trial of PCLX-001 in patients with relapsed/refractory B-cell Non-Hodgkin’s Lymphoma and advanced solid malignancies is currently in progress, and a second Phase 1 trial in patients with relapsed or refractory acute myeloid leukemia (AML) is planned to start Q2 2023. The FDA has granted PCLX-001 Orphan Drug Designation and Fast Track Designation for the treatment of adult patients with relapsed or refractory acute myeloid leukemia.
About Pacylex Pharmaceuticals
Pacylex is a clinical-stage pharmaceutical company headquartered in Edmonton, Alberta, Canada, developing a first-in-class, once daily oral cancer therapy with a novel targeted mechanism of action, PCLX-001. PCLX-001 is the lead drug in a new class of N-myristoyl-transferase (NMT) inhibitors, enabling Pacylex to exploit myristoylation as a new clinical target for cancer treatment. Pacylex is conducting a Phase 1 dose escalation study in Canada in patients with non-Hodgkin lymphoma and solid tumors. Pacylex received support from an Alberta Innovates AICE grant in 2020, and the research leading to this breakthrough was supported in part by the Alberta Cancer Foundation and the Cure Cancer Foundation. A second Phase 1 dose escalation study in patients with acute myeloid leukemia (AML) being supported by the US Department of Defense is planned to start Q2 2023.
Pacylex is a clinical-stage pharmaceutical company headquartered in Edmonton, Alberta, Canada, developing a first-in-class, once daily oral cancer therapy with a novel targeted mechanism of action, PCLX-001. PCLX-001 is the lead drug in a new class of N-myristoyl-transferase (NMT) inhibitors, enabling Pacylex to exploit myristoylation as a new clinical target for cancer treatment. Pacylex is conducting a Phase 1 dose escalation study in Canada in patients with non-Hodgkin lymphoma and solid tumors. Pacylex received support from an Alberta Innovates AICE grant in 2020, and the research leading to this breakthrough was supported in part by the Alberta Cancer Foundation and the Cure Cancer Foundation. A second Phase 1 dose escalation study in patients with acute myeloid leukemia (AML) being supported by the US Department of Defense is planned to start Q2 2023.
About Biotech Showcase
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 15th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.
For more information:
Pacylex Pharmaceuticals
Contact: Michael J. Weickert
Contact: Michael J. Weickert
CEO, Pacylex Pharmaceuticals, Inc.
P: 650-218-1840
Twitter @Pacylex (https://twitter.com/pacylex)
LinkedIn (www.linkedin.com/company/pacylex-pharma)
Facebook (https://www.facebook.com/pacylex)
Reportable page: (https://pacylex.reportablenews.com/)
#cancer, #lymphoma, #leukemia, #albertacancer, #Pacylex, #PCLX001, #UAlberta; #UAlberta_FoMD; #Worldslongestgame, #ASH22, #MDACC, #AML
Contacts:
Michael Weickert Ph.D
650-218-1840
michael.weickert@pacylex.com
Source: Pacylex
Distributed by: Reportable, Inc.
WRITTEN BY
Reportable
More from Reportable
